- |||||||||| atorvastatin/Ω-3 fatty acid (UI018) / Korea United Pharm
PK/PD data, Journal: Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers. (Pubmed Central) - Aug 27, 2022 The GMRs (90% Cis) for the co-administration at steady state of atorvastatin, 2-OH-atorvastatin, DHA, and EPA were 1.150 (0.990-1.335), 1.301 (1.2707-1.1401), 0.320 (0.243-0.422), and 0.589 (0.487-0.712), respectively. The 90% CIs for most primary endpoints were outside the range of typical bioequivalence, indicating a pharmacokinetic interaction between atorvastatin and omega-3.
- |||||||||| atorvastatin/?-3 fatty acid (UI018) / Korea United Pharm
Enrollment closed, Trial primary completion date: Study to Evaluate the Safety and PK of UI018 (clinicaltrials.gov) - Dec 21, 2021 P1, N=44, Active, not recruiting, The 90% CIs for most primary endpoints were outside the range of typical bioequivalence, indicating a pharmacokinetic interaction between atorvastatin and omega-3. Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2022 --> Nov 2021
|